Molecular Targeted Therapy

• 

  Subject Areas on Research

  • A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product. 
  • A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma. 
  • A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. 
  • A neurogenetics approach to understanding individual differences in brain, behavior, and risk for psychopathology. 
  • A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. 
  • A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. 
  • A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. 
  • A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. 
  • A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. 
  • A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. 
  • APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer's. 
  • Accepting risk in the acceleration of drug development for rare cancers. 
  • Active-learning strategies in computer-assisted drug discovery. 
  • Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. 
  • Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer. 
  • Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. 
  • Advanced Melanoma: Resistance Mechanisms to Current Therapies. 
  • Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities. 
  • Alternative Splicing of G Protein-Coupled Receptors: Relevance to Pain Management. 
  • American Society of Clinical Oncology 2013 top five list in oncology. 
  • An introduction to small non-coding RNAs: miRNA and snoRNA. 
  • Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. 
  • Antibody-based immunotherapy for malignant glioma. 
  • Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. 
  • Application of combined omics platforms to accelerate biomedical discovery in diabesity. 
  • Applications of RNA interference high-throughput screening technology in cancer biology and virology. 
  • Arrestin interaction with E3 ubiquitin ligases and deubiquitinases: functional and therapeutic implications. 
  • Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis. 
  • Atherosclerosis: Recent trials, new targets and future directions. 
  • BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. 
  • BRAF in melanoma: current strategies and future directions. 
  • Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. 
  • Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. 
  • Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy. 
  • Breast cancer, version 3.2013: featured updates to the NCCN guidelines. 
  • CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. 
  • CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC. 
  • CLT1 targets bladder cancer through integrin α5β1 and CLIC3. 
  • Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. 
  • Cancer therapy-related complications in the bowel and mesentery: an imaging perspective. 
  • Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer. 
  • Cardio-oncology in clinical studies and real life. 
  • Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. 
  • Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. 
  • Cell surface GRP78 signaling: An emerging role as a transcriptional modulator in cancer. 
  • Cellular and molecular targeting for nanotherapeutics in transplantation tolerance. 
  • Changes in Nutritional Status Impact Immune Cell Metabolism and Function. 
  • Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading. 
  • Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. 
  • Checkpoint inhibitors in hematological malignancies. 
  • Chemokine Signaling in Allergic Contact Dermatitis: Toward Targeted Therapies. 
  • Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. 
  • Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma. 
  • Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. 
  • Colorectal cancer models for novel drug discovery. 
  • Combinations of Bevacizumab With Cancer Immunotherapy. 
  • Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. 
  • Complexity of Delivering Precision Medicine: Opportunities and Challenges. 
  • Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies. 
  • Comprehensive molecular characterization of urothelial bladder carcinoma. 
  • Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. 
  • Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma. 
  • Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer. 
  • Copper signaling axis as a target for prostate cancer therapeutics. 
  • Current and Emerging Treatment for Diabetic Macular Edema. 
  • Cytotoxic T-lymphocyte-associated antigen-4. 
  • Dawn of a New RAMPage. 
  • Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. 
  • Delivery systems exploiting natural cell transport processes of macromolecules for intracellular targeting of Auger electron emitters. 
  • Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. 
  • Designing a broad-spectrum integrative approach for cancer prevention and treatment. 
  • Discovery and characterization of small molecules that target the GTPase Ral. 
  • Discovery of Dual-Stage Malaria Inhibitors with New Targets. 
  • Discovery of Tamoxifen and N-Desmethyl Tamoxifen Protein Targets in MCF-7 Cells Using Large-Scale Protein Folding and Stability Measurements. 
  • Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. 
  • Drug design from the cryptic inhibitor envelope. 
  • Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters. 
  • EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. 
  • EGFR Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance? 
  • Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. 
  • Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. 
  • Emerging therapeutic targets for patients with advanced prostate cancer. 
  • Emerging therapeutic targets for soft tissue sarcoma. 
  • Endoglin Targeting: Lessons Learned and Questions That Remain. 
  • Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. 
  • Esophageal and esophagogastric junction cancers. 
  • Estrogen-Related Receptor Alpha: An Under-Appreciated Potential Target for the Treatment of Metabolic Diseases. 
  • Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. 
  • Evolving story of autoantibodies in systemic lupus erythematosus. 
  • Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. 
  • FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target. 
  • Fibroblast growth factor 21 mediates specific glucagon actions. 
  • Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. 
  • G Protein-coupled Receptor Biased Agonism. 
  • G-protein-coupled receptors signaling pathways in new antiplatelet drug development. 
  • GPCRs and arrestins in airways: implications for asthma. 
  • Galectin-3 as a Therapeutic Target for NSAID-Induced Intestinal Ulcers. 
  • Gastric cancer-molecular and clinical dimensions. 
  • Genetic heterogeneity of diffuse large B-cell lymphoma. 
  • Genetic lesions in diffuse large B-cell lymphomas. 
  • Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study. 
  • Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). 
  • Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. 
  • Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors). 
  • Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis. 
  • Glutamine Metabolism in Cancer: Understanding the Heterogeneity. 
  • Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. 
  • HER2 testing in metastatic colorectal cancer: ready for prime time? 
  • HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. 
  • HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. 
  • HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles. 
  • Heterogeneity of tumor-induced gene expression changes in the human metabolic network. 
  • Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer. 
  • How can we optimize treatment of HER2-positive metastatic breast cancer? 
  • Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. 
  • IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma. 
  • Identifying new small molecule anti-invasive compounds for glioma treatment. 
  • Immune Checkpoint Inhibitors for Brain Metastases. 
  • Immune checkpoint blockade: Releasing the brake towards hematological malignancies. 
  • Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. 
  • Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma. 
  • Immunotherapy for osteosarcoma: Where do we go from here? 
  • Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. 
  • Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. 
  • Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology. 
  • Implications of HER2-targeted therapy on extent of surgery for early-stage breast cancer. 
  • Improving evidence developed from population-level experience with targeted agents. 
  • Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials. 
  • Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology. 
  • Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. 
  • Inhibition of endoglin-GIPC interaction inhibits pancreatic cancer cell growth. 
  • Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers. 
  • Integrated genomic characterization of oesophageal carcinoma. 
  • Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability. 
  • Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery. 
  • Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. 
  • Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma. 
  • Is tumor response important for renal carcinoma? 
  • LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. 
  • Leveraging Nuclear Receptors as Targets for Pathological Ocular Vascular Diseases. 
  • Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. 
  • Lipids and Their Effects in Chronic Lymphocytic Leukemia. 
  • Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis. 
  • Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease. 
  • MEK inhibition in the treatment of advanced melanoma. 
  • MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. 
  • MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. 
  • Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas. 
  • Management of Immunotherapy-Related Toxicities, Version 1.2019. 
  • Mapping the Pathways of Resistance to Targeted Therapies. 
  • Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. 
  • Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. 
  • Melanoma brain metastasis: overview of current management and emerging targeted therapies. 
  • Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. 
  • Metabolic Barriers to T Cell Function in Tumors. 
  • Metabolomics in cancer research and emerging applications in clinical oncology. 
  • Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease. 
  • Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. 
  • Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. 
  • Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets. 
  • Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. 
  • Modulation of the Coagulation Cascade Using Aptamers. 
  • Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. 
  • Molecular Imaging and Precision Medicine in Head and Neck Cancer. 
  • Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology. 
  • Molecular Markers and Targeted Therapeutics in Metastatic Tumors of the Spine: Changing the Treatment Paradigms. 
  • Molecular pathways and therapeutic targets in lung cancer. 
  • Molecular pathways: the metabolic regulator estrogen-related receptor α as a therapeutic target in cancer. 
  • Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. 
  • N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. 
  • NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. 
  • NCCN Guidelines Insights: Melanoma, Version 3.2016. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. 
  • NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms. 
  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. 
  • Neuro-ophthalmic side effects of molecularly targeted cancer drugs. 
  • Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy. 
  • New betulinic acid derivatives as potent proteasome inhibitors. 
  • New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. 
  • Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. 
  • Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. 
  • Novel medication targets for the treatment of alcoholism: preclinical studies. 
  • Novel therapeutic targets of tumor metabolism. 
  • Nox1 in cardiovascular diseases: regulation and pathophysiology. 
  • On the quantitative assessment of predictive biomarkers. 
  • Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies. 
  • Opportunities for the Cardiovascular Community in the Precision Medicine Initiative. 
  • Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. 
  • Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. 
  • Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. 
  • Ovarian cancer, version 3.2012. 
  • Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. 
  • Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. 
  • PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. 
  • PTEN reconstitution alters glioma responses to c-Met pathway inhibition. 
  • Pathophysiological significance of c-jun N-terminal kinase in acetaminophen hepatotoxicity. 
  • Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. 
  • Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. 
  • Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? 
  • Personalized targeted therapy for esophageal squamous cell carcinoma. 
  • Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. 
  • Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells. 
  • Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. 
  • Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. 
  • Phase II cancer clinical trials for biomarker-guided treatments. 
  • Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. 
  • Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis. 
  • Pitfalls of Combining Novel Agents in Lymphoma. 
  • Precision Medicine and PET/Computed Tomography: Challenges and Implementation. 
  • Precision Medicine and PET/Computed Tomography: Time Has Arrived. 
  • Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope. 
  • Proceedings of the fifth international RASopathies symposium: When development and cancer intersect. 
  • Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. 
  • Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. 
  • RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. 
  • Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. 
  • Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry. 
  • Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. 
  • Recent Insights into Notch Signaling in Embryonal Rhabdomyosarcoma. 
  • Renal Pre-Competitive Consortium (RPC2): discovering therapeutic targets together. 
  • Reply to J.J. Tao et al. 
  • Resistance exercise training in patients with genitourinary cancers to mitigate treatment-related skeletal muscle loss. 
  • Rethinking Nuclear Receptors as Potential Therapeutic Targets for Retinal Diseases. 
  • Role of the ABL tyrosine kinases in the epithelial-mesenchymal transition and the metastatic cascade. 
  • SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. 
  • Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. 
  • Specificity Protein Transcription Factors and Cancer: Opportunities for Drug Development. 
  • Structure, inhibition, and regulation of essential lipid A enzymes. 
  • Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. 
  • Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. 
  • Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma. 
  • Targeted Nrf2 activation therapy with RTA 408 enhances regenerative capacity of diabetic wounds. 
  • Targeted Therapy and Immunosuppression in the Tumor Microenvironment. 
  • Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. 
  • Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type? 
  • Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. 
  • Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction. 
  • Targeted therapies and outcomes data: the inflammatory hypothesis matures. 
  • Targeted therapy for infants with diencephalic syndrome: A case report and review of management strategies. 
  • Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. 
  • Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. 
  • Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain. 
  • Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. 
  • Targeting MET Amplification with Crizotinib in a Case of Sinonasal Undifferentiated Carcinoma. 
  • Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does "X" Really Mark the Spot? 
  • Targeting Pim Kinases and DAPK3 to Control Hypertension. 
  • Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. 
  • Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. 
  • Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. 
  • Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway. 
  • Targeting nucleolin for better survival in diffuse large B-cell lymphoma. 
  • Targeting phosphorylation of eukaryotic initiation factor-2α to treat human disease. 
  • Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases. 
  • Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma. 
  • Targeting the SUMO pathway for neuroprotection in brain ischaemia. 
  • Targeting the epigenome in ovarian cancer. 
  • Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. 
  • Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. 
  • Targeting the programmed death-1 pathway in lymphoid neoplasms. 
  • Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. 
  • The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. 
  • The Aryl Hydrocarbon Receptor: A Mediator and Potential Therapeutic Target for Ocular and Non-Ocular Neurodegenerative Diseases. 
  • The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. 
  • The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. 
  • The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. 
  • The Skp2 Pathway: A Critical Target for Cancer Therapy. 
  • The antifungal pipeline: a reality check. 
  • The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. 
  • The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. 
  • The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. 
  • The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. 
  • The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? 
  • The implications of IDH mutations for cancer development and therapy. 
  • The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. 
  • The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. 
  • The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure. 
  • The rise of genomic profiling in ovarian cancer. 
  • The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). 
  • The whole-genome landscape of medulloblastoma subtypes. 
  • Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC. 
  • Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. 
  • Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions. 
  • Therapy of inflammatory bowel disease: what to expect in the next decade. 
  • Toxin-based targeted therapy for malignant brain tumors. 
  • Trametinib (GSK1120212) in the treatment of melanoma. 
  • Translating protein phosphatase research into treatments for neurodegenerative diseases. 
  • Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression. 
  • Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward? 
  • Tumor Heterogeneity and Therapeutic Resistance. 
  • Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. 
  • Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre. 
  • Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response. 
  • Vorapaxar: a novel protease-activated receptor-1 inhibitor. 
  • Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. 
  • What Is the Optimal Treatment of Papillary Thyroid Cancer? 
  • What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care. 
  • Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. 
  • Wnt Signaling and Drug Resistance in Cancer. 
  • [Acute myeloid leukemia]. 
  • Β-arrestin: a signaling molecule and potential therapeutic target for heart failure. 
  • β-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Chitneni, Satish K., Associate Professor in Radiology, Radiology
  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • Hanks, Brent A., Associate Professor of Medicine, Pharmacology & Cancer Biology
  • Luftig, Micah Alan, Professor of Molecular Genetics and Microbiology, Cell Biology
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering